Bioceres Crop Solutions Reports Fiscal First Quarter 2027 Financial and Operational Results

Bioceres Crop Solutions Reports Fiscal First Quarter 2027 Financial and Operational Results
Corporate News | Financial Results | Agricultural Innovation

Bioceres Crop Solutions Reports Fiscal First Quarter 2027 Financial and Operational Results

November 11, 2026 | Rosario, Argentina

Total revenues were $53.8 million in 1Q27. Net loss was $10.8 million and Adjusted EBITDA was $5.3 million.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX), a company focused on developing and commercialising agricultural productivity solutions designed to regenerate farming ecosystems and improve crop resilience to climate change, announced its financial and operational results for the first quarter of fiscal year 2027, ended September 30, 2026.

All financial figures are presented in US dollars and follow International Financial Reporting Standards (IFRS). Year-over-year comparisons are used throughout unless otherwise specified.

$53.8M Total Revenue – 1Q27
$18.8M Gross Profit
$5.3M Adjusted EBITDA
35.0% Gross Margin
$10.8M Net Loss
22% Revenue Decline YoY

Presentation of Results

In January 2026, Bioceres’ Pro Farm Group (PFG) business underwent a foreclosure auction. For accounting purposes, PFG has been classified as discontinued operations, with its assets valued at $15 million, corresponding to the amount awarded to an entity associated with a noteholder.

The company continues to challenge the acceleration of the relevant notes and the foreclosure process through ongoing legal proceedings.

On October 21, 2026, a court allowed the company’s claim concerning potential violations of Article 9 of the New York Uniform Commercial Code and the commercial reasonableness of the foreclosure process to proceed to the discovery stage.

Unless otherwise specified, the financial results presented in this announcement relate to continuing operations. Previous-year figures have also been adjusted to exclude the PFG business.

Financial and Business Highlights

  • Total revenue reached $53.8 million, representing a 22% year-over-year decline.
  • Gross profit decreased 39% to $18.8 million, with gross margin declining to 35%.
  • Selling, General and Administrative (SG&A) expenses remained broadly stable at $17.4 million.
  • Net loss from continuing operations increased to $10.8 million compared with $4.7 million in 1Q26.
  • Adjusted EBITDA was $5.3 million, compared with $13.9 million in the previous year’s quarter.
  • Adjusted EBITDA improved sequentially for the second consecutive quarter.

Management Review

The first quarter reflected a slower start to the new financial year. Sales of soybean-related seed treatments began later in the quarter, with some commercial activity shifting into the following reporting period. Limited financial flexibility also affected certain product categories where market conditions required longer customer financing arrangements. Greater pressure on growers’ operating costs increased price sensitivity and influenced purchasing decisions for differentiated agricultural technologies. Despite lower volumes and an unfavourable product mix, the company maintained operating expense discipline. Management remains focused on improving commercial execution, strengthening operational performance and maintaining financial discipline.

Federico Trucco
Chief Executive Officer, Bioceres Crop Solutions

Key Financial Metrics

Table 1: First Quarter 2027 Financial Performance

Figures in millions of US dollars, except percentages.

Financial Metric 1Q26 1Q27 Change
Crop Protection Revenue33.229.1-12%
Seed and Integrated Products12.55.9-53%
Crop Nutrition Revenue23.418.8-20%
Total Revenue69.153.8-22%
Gross Profit30.818.8-39%
Gross Margin44.5%35.0%-955 bps
Net Loss(4.7)(10.8)-127%
Adjusted EBITDA13.95.3-62%

Fiscal First Quarter 2027 Financial Results

1. Revenues by Business Segment

Revenue for the first quarter totalled $53.8 million, down from $69.1 million in the corresponding period last year. The decline reflected changes in commercial activity across the company’s soybean-related portfolio and stronger competition in Argentina, where growers became more price-sensitive towards differentiated agricultural inputs.

Business Segment 1Q26 ($M) 1Q27 ($M) Change
Crop Protection33.229.1-12%
Seed and Integrated Products12.55.9-53%
Crop Nutrition23.418.8-20%
Total Revenue69.153.8-22%

Crop Protection: Revenue declined 12% to $29.1 million, mainly because of lower adjuvant sales.

Seed and Integrated Products: Revenue decreased 53% to $5.9 million. The decline reflected the discontinuation of seed sales, lower seed-treatment package volumes and a shift in some soybean-related purchases into the second quarter.

Crop Nutrition: Revenue declined 20% to $18.8 million, primarily due to lower sales of microbeaded fertilisers and inoculants.

2. Gross Profit and Margin

Gross profit decreased 39% to $18.8 million from $30.8 million in 1Q26. Gross margin declined from 44.5% to 35%, primarily due to lower sales volumes and an unfavourable revenue mix.

A greater contribution from lower-margin raw material sales to Synertech, the company’s microbeaded fertiliser manufacturing joint venture, also affected consolidated margins.

Business Segment 1Q26 ($M) 1Q27 ($M) Change
Crop Protection13.68.1-40%
Seed and Integrated Products7.64.2-44%
Crop Nutrition9.66.4-33%
Total Gross Profit30.818.8-39%
Gross Margin44.5%35.0%-955 bps

Crop Protection gross profit decreased 40% to $8.1 million, with margins declining from 41% to 28%. Lower sales of higher-margin adjuvants and a greater contribution from lower-margin products influenced performance.

Seed and Integrated Products gross profit declined 44% to $4.2 million. However, its gross margin improved by approximately 11 percentage points following the discontinuation of lower-margin seed sales.

Crop Nutrition gross profit decreased 33% to $6.4 million. Lower microbeaded fertiliser and inoculant volumes, together with a reduced contribution from higher-margin inoculant revenues, affected segment performance.

3. Operating Expenses

Selling, General and Administrative expenses were $17.4 million in 1Q27, compared with $17.2 million in 1Q26. The company maintained cost discipline despite inflationary pressures in its predominantly Argentine peso-denominated cost base, particularly freight and transportation expenses.

Depreciation and amortisation, share-based incentives and transactional expenses together amounted to $2.1 million, compared with $2.0 million in the prior-year quarter.

Research and Development

R&D expenses declined by 51%.

Total research and development expenditure was $1.8 million in 1Q27, compared with $3.7 million in 1Q26. Depreciation and amortisation included in R&D expenses amounted to $1.1 million, compared with $1.2 million in the previous year.

4. Net Loss and Adjusted EBITDA

The net loss from continuing operations reached $10.8 million in 1Q27, compared with $4.7 million in the corresponding period last year. The wider loss was primarily associated with lower gross profit, partially offset by lower operating expenses and improved financial results.

Adjusted EBITDA was $5.3 million, down from $13.9 million in 1Q26. Nevertheless, the company recorded sequential improvement for the second consecutive quarter.

Period Adjusted EBITDA ($M)
3Q26(0.6)
4Q260.6
1Q275.3

5. Financial Income and Loss

Net financial results were negative $10.4 million in 1Q27, compared with negative $11.9 million in the prior-year quarter.

Financial Item 1Q26 ($M) 1Q27 ($M)
Interest Expenses(7.6)(10.0)
Financial Commissions(0.6)(0.4)
Fair Value, FX and Other Financial Results(3.8)0.1
Net Financial Result(11.9)(10.4)

The improvement was mainly associated with a smaller negative impact from foreign exchange, fair-value changes and other financial items. This was partly offset by higher interest expenses related to secured notes and the renegotiation of local debt obligations.

Balance Sheet Highlights

Table 5: Capitalisation and Debt

Figures in millions of US dollars.

Financial Item September 30, 2025 September 30, 2026
Secured Notes103.6112.0
Short-Term Borrowings85.156.1
Long-Term Borrowings53.853.6
Cash and Cash Equivalents(15.5)(7.5)
Other Short-Term Investments(1.1)(1.2)
Net Financial Debt225.9213.0

Total financial debt stood at $221.7 million on September 30, 2026, slightly below the preceding quarter. Cash, cash equivalents and other short-term investments amounted to $8.7 million, resulting in net financial debt of $213 million.

This compared with net financial debt of $225.9 million in September 2025 and $217 million in June 2026.

Following the noteholder acceleration notices, approximately $112 million in secured notes remained classified as short-term debt. The company continues to dispute the acceleration and foreclosure proceedings.

Unaudited Consolidated Financial Statements

Table 6: Consolidated Statement of Comprehensive Income

Figures in millions of US dollars. Three-month periods ended September 30.

Financial Item 2025 2026
Revenue from Contracts with Customers69.053.9
Biological Asset Fair Value Changes0.2(0.2)
Cost of Sales(38.4)(35.0)
Gross Profit30.818.8
Gross Margin45%35%
Operating Expenses(20.8)(19.2)
Share of Profit of JV0.31.1
Change in Agricultural Product NRV(0.3)0.0
Other Income / Expenses(0.2)0.1
Operating Profit9.70.9
Financial Result(11.9)(10.4)
Loss Before Income Tax(2.3)(9.5)
Income Tax(2.5)(1.3)
Net Loss(4.7)(10.8)
Discontinued Operations Loss(2.7)–
Other Comprehensive Profit / Loss(0.3)0.1
Total Comprehensive Loss(7.8)(10.7)

Statement of Financial Position – Assets

Figures in millions of US dollars.

Assets 30 June 2026 30 September 2026
Cash and Cash Equivalents11.27.5
Other Financial Assets1.01.2
Trade Receivables – Current98.296.3
Other Receivables – Current12.114.1
Recoverable Income Tax1.41.4
Inventories46.451.8
Biological Assets0.6–
Assets Subject to Foreclosure44.4–
Total Current Assets215.4172.3
Trade Receivables – Non-current0.70.4
Other Receivables – Non-current16.216.5
Recoverable Income Tax–0.0
Deferred Tax Assets0.30.3
Investments in Joint Ventures40.841.9
Property, Plant and Equipment60.759.4
Intangible Assets74.773.6
Goodwill28.628.6
Right of Use Asset11.010.4
Total Non-current Assets232.8231.1
Total Assets448.2403.4

Statement of Financial Position – Liabilities and Equity

Liabilities and Equity 30 June 2026 30 September 2026
Trade and Other Payables – Current57.762.6
Borrowings – Current47.356.1
Employee Benefits and Social Security4.85.7
Deferred Revenue and Customer Advances2.12.1
Income Tax Payable4.96.0
Acquisition Consideration0.00.0
Secured Notes122.0112.0
Lease Liabilities – Current2.11.7
Liabilities Subject to Foreclosure29.4–
Total Current Liabilities270.3246.1
Trade and Other Payables – Non-current42.038.9
Borrowings – Non-current60.053.6
Deferred Revenue and Advances1.41.4
Joint Ventures and Associates1.11.1
Deferred Tax Liabilities23.923.5
Provisions6.36.3
Acquisition Consideration0.40.4
Lease Liabilities – Non-current8.88.7
Total Non-current Liabilities143.8134.0
Total Liabilities414.2380.1
Total Equity34.123.4
Total Equity and Liabilities448.2403.4

Adjusted EBITDA Reconciliation

The company uses Adjusted EBITDA as a supplementary indicator of financial and operating performance. It is calculated by adjusting net profit or loss for financial income and costs, taxes, depreciation, amortisation, share-based compensation and specified non-recurring expenses.

Reconciliation Item 1Q26 ($M) 1Q27 ($M)
Profit / (Loss) for the Period(4.7)(10.8)
Income Tax2.51.3
Financial Results11.910.4
Depreciation and Amortisation3.53.3
Stock-based Compensation–(0.0)
Non-recurring and Transaction Expenses0.61.2
Adjusted EBITDA13.95.3

Management considers Adjusted EBITDA useful as an additional measure of underlying operating performance. However, it is not an IFRS financial measure and should not be viewed independently of the company’s reported financial statements.

Forward-Looking Statements

Use of Non-IFRS Financial Information

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) develops and commercialises agricultural productivity solutions designed to regenerate agricultural ecosystems and improve the resilience of crops to climate change.

Its solutions aim to create economic incentives for farmers and other agricultural stakeholders to adopt more environmentally friendly production practices.

The company’s business activities include agricultural technologies, crop protection, seed and integrated products, crop nutrition and biological solutions.

For additional information, visit the company’s official website: Bioceres Crop Solutions .

Investor Relations Contact

Paula Savanti
Head of Investor Relations
Email: investorrelations@biocerescrops.com

Source: Bioceres Crop Solutions Corp. | Fiscal First Quarter 2027 Financial and Operational Results | November 11, 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *


View More →